Drug Profile
SHR 2554
Alternative Names: EBI 2554; SHR-2554Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Chinese PLA General Hospital; Fudan University; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Peripheral T-cell lymphoma
- Phase II HER2 negative breast cancer
- Phase I/II B-cell lymphoma; Prostate cancer; Solid tumours
- Phase I Malignant melanoma; Non-Hodgkin's lymphoma
Most Recent Events
- 19 Apr 2024 Jiangsu HengRui Medicine plans a phase II trial for Follicular Lymphoma (Second-line therapy or greater) in China in April 2024 (NCT06368167)
- 01 Feb 2024 Phase-III clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater, Combination therapy) in China (PO) (NCT06122389)
- 18 Dec 2023 Jiangsu HengRui Medicine plans a phase Ib/II trial for Peripheral T-cell lymphoma (Treatment-naïve, In adults, In the elderly) (unspecified) (NCT06173999)